Skip to main content

Table 1 No significant difference in patient characteristics and other operative data between the groups

From: 50% efficacy dose of intravenous lidocaine in supressing sufentanil-induced cough in children: a randomised controlled trial

 

Group A

(n = 47)

Group B

(n = 47)

Group C

(n = 47)

Group D

(n = 47)

Age (years)

5.55 ± 2.02

6.02 ± 2.35

5.77 ± 1.91

5.98 ± 1.67

Height (cm)

118.34 ± 14.21

120.60 ± 16.02

117.81 ± 13.65

120.49 ± 12.02

Weight (kg)

22.88 ± 7.60

23.57 ± 8.57

22.57 ± 6.65

25.03 ± 7.22

BMI(kg/m2)

15.96 ± 2.65

15.75 ± 2.22

16.04 ± 2.27

16.97 ± 2.75

Sex (M⁄ F)

26/21

27/20

29/18

29/18

ASA(I/II)

47/0

47/0

47/0

47/0

time of operation(min)

29.74 ± 11.14

29.40 ± 11.10

29.43 ± 13.68

27.34 ± 11.95

time of extubation(min)

11.55 ± 3.32

13.72 ± 3.30

13.70 ± 3.59

13.68 ± 3.58

incidence of laryngospasm

0

0

0

0

incidence of bronchospasm

0

0

0

0

incidence of stridor

0

0

0

0

tonsillectomy with or without adenoidectomy

45/2

47/0

47/0

46/1

  1. Values are mean ± standard deviation or numbers. †P < 0.05 vs. Group A
  2. Group A, Lidocaine 0 mg/kg IV; Group B, Lidocaine 1 mg/kg IV; Group C, Lidocaine 1.5 mg/kg IV; Group D, Lidocaine 2 mg/kg IV